Aim: To support clinical efficacy studies where proof of concept in humans has been achieved (EME is earlier in the development pathway than HTA).
Funding: No fixed limits on duration or funding.
Process: Two-stage process. It is vital that feedback given at the first stage is addressed as this can change the application quite considerably. The process takes 8 months. About 20% of bids go through to the second stage and, of those, about 50% are funded.
Criteria: Applications will be judged on the following criteria: